NCT03891901View on ClinicalTrials.gov

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

August 30, 2022

Study Completion Date

August 30, 2022

Conditions
Tuberculosis
Interventions
DRUG

Imatinib

Tablets, administered orally

DRUG

Isoniazid

300 mg tablets, administered orally

DRUG

Rifabutin

300 mg capsules, administered orally

Trial Locations (1)

30332

Emory University DAIDS TB Non-Network CRS, Atlanta

Sponsors

Collaborators (1)

Aurum Institute
All Listed Sponsors
collaborator

Emory University

OTHER

collaborator

University of Pennsylvania

OTHER

collaborator

Aurum Institute

OTHER

collaborator

University of Florida

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH